Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion

被引:16
|
作者
Gewaily, Dina [1 ]
Greenberg, Paul B. [1 ]
机构
[1] Brown Univ, Warren Alpert Med Sch, VA Med Ctr,Sect Ophthalmol, Rhode Isl Hosp,Div Ophthalmol, Providence, RI 02908 USA
关键词
ENDOTHELIAL GROWTH-FACTOR; TRIAMCINOLONE ACETONIDE; INJECTION; ENDOPHTHALMITIS; TOXICITY; MANAGEMENT; EFFICACY; THERAPY; CRVO;
D O I
10.1002/14651858.CD007324.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Central retinal vein occlusion (CRVO) is a common retinal vascular abnormality associated with conditions such as hypertension, diabetes, glaucoma, and a wide variety of hematologic disorders. Macular edema (ME) represents an important vision-threatening complication of CRVO. There is no proven treatment; laser photocoagulation is not effective in treating cystoid macular edema secondary to CRVO. Intravitreal steroids, such as triamcinolone acetonide, have been utilized to treat macular edema stemming from a variety of etiologies and may represent a treatment option for CRVO-ME. Objectives The objective of this review was to explore the effectiveness and safety of intravitreal steroids in the treatment of CRVO-ME. Search strategy We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2008), MEDLINE (January 1950 to November 2008) and EMBASE (January 1980 to November 2008). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 5 November 2008. For all included primary studies, we used The Science Citation Index and manually reviewed reference lists to identify other possible relevant trials. We contacted researchers in the field, currently working on a randomized controlled trial (RCT) on this topic (The Standard Care versus Corticosteroid for Retinal Vein Occlusion-SCORE study), for information on additional current, past, or unpublished trials. Selection criteria We considered RCTs that compared intravitreal steroids of any dosage/duration to observation in the treatment of CRVO-ME for inclusion in this review. We focused on studies that included individuals of any age or gender with unilateral or bilateral disease, with a minimum of six months follow up. Secondarily we considered non-randomized studies with the same criteria for description of evidence, however we did not conduct a separate electronic search for finding all non-randomized studies. Data collection and analysis We found no RCTs that met the inclusion criteria after independent and duplicate review of the search results. Main results We found no relevant RCTs and therefore performed no meta-analysis. Evidence from non-randomized studies is reported in this review. Authors' conclusions There is inadequate evidence for the use of intravitreal steroids for CRVO-ME due to a paucity of RCTs and well-designed observational studies on the topic; therefore, it is still an experimental procedure.
引用
收藏
页数:29
相关论文
共 50 条
  • [1] Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion
    Gewaily, Dina
    Muthuswamy, Karthikeyan
    Greenberg, Paul B.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (09):
  • [2] INTRAVITREAL RANIBIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION
    Risard, Sarah M.
    Pieramici, Dante J.
    Rabena, Melvin D.
    Basefsky, Jessica C.
    Avery, Robert L.
    Castellarin, Alessandro A.
    Nasir, Ma'an A.
    See, Robert F.
    Couvillion, Stephen S.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (06): : 1060 - 1067
  • [3] EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION
    Lotfy, Ayman
    Solaiman, Kamal A. M.
    Abdelrahman, Ayman
    Samir, Ahmed
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (09): : 1795 - 1800
  • [4] Intravitreal Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusion
    Parajuli, Anil
    Joshi, Purushottam
    Subedi, Prabha
    Pradhan, Chandni
    [J]. NEPALESE JOURNAL OF OPHTHALMOLOGY, 2020, 12 (02) : 281 - 289
  • [5] Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion
    Kim, Moosang
    Yu, Seung-Young
    Kim, Eung-Suk
    Bae, So Hyun
    Park, Jung Hyun
    Yu, Hyeong Gon
    Kwak, Hyung-Woo
    [J]. OPHTHALMOLOGICA, 2012, 227 (03) : 132 - 138
  • [6] PROSPECTIVE STUDY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION
    Ding, Xiaoyan
    Li, Jiaqing
    Hu, Xuting
    Yu, Shanshan
    Pan, Jianying
    Tang, Shibo
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (05): : 838 - 845
  • [7] Aflibercept versus dexamethasone in macular edema secondary to central retinal vein occlusion
    Garreton, Rodolfo
    Gonzalez, Raul
    [J]. MEDWAVE, 2019, 19 (11):
  • [8] INTRAVITREAL BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION
    Ehlers, Justis P.
    Decroos, Francis Char
    Fekrat, Sharon
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (09): : 1856 - 1862
  • [9] Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion
    Udaondo, Patricia
    Garcia-Delpech, Salvador
    Salom, David
    Garcia-Pous, Maria
    Diaz-Llopis, Manuel
    [J]. CLINICAL OPHTHALMOLOGY, 2011, 5 : 941 - 944
  • [10] Intravitreal triamcinolone injection for macular edema secondary to retinal vein occlusion
    Radhakrishnan, R
    Roth, DB
    Yarian, L
    Green, SN
    Wheatley, HM
    Friedman, ES
    Keyser, BJ
    Leff, SR
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46